Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $90.1 million.

  • Denali Therapeutics' Total Current Liabilities rose 350.54% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 350.54%. This contributed to the annual value of $102.2 million for FY2024, which is 3106.61% up from last year.
  • Denali Therapeutics' Total Current Liabilities amounted to $90.1 million in Q3 2025, which was up 350.54% from $91.1 million recorded in Q2 2025.
  • Denali Therapeutics' Total Current Liabilities' 5-year high stood at $391.1 million during Q1 2023, with a 5-year trough of $51.4 million in Q2 2021.
  • Over the past 5 years, Denali Therapeutics' median Total Current Liabilities value was $90.1 million (recorded in 2025), while the average stood at $167.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 57719.6% in 2022, then plummeted by 8026.45% in 2023.
  • Over the past 5 years, Denali Therapeutics' Total Current Liabilities (Quarter) stood at $378.2 million in 2021, then decreased by 3.79% to $363.9 million in 2022, then tumbled by 78.57% to $78.0 million in 2023, then surged by 31.07% to $102.2 million in 2024, then decreased by 11.8% to $90.1 million in 2025.
  • Its Total Current Liabilities stands at $90.1 million for Q3 2025, versus $91.1 million for Q2 2025 and $91.9 million for Q1 2025.